NYSE - Delayed Quote • USD
Dr. Reddy's Laboratories Limited (RDY)
At close: April 24 at 4:00 PM EDT
After hours: April 24 at 4:08 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 5 | 1 | 25 | 25 |
Avg. Estimate | 0.82 | 0.96 | 3.8 | 3.97 |
Low Estimate | 0.62 | 0.96 | 2.21 | 2.67 |
High Estimate | 1.07 | 0.96 | 4.16 | 4.51 |
Year Ago EPS | 0.7 | 1.01 | 3.3 | 3.8 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 15 | -- | 27 | 26 |
Avg. Estimate | 852.52M | -- | 3.31B | 3.53B |
Low Estimate | 763.84M | -- | 2.88B | 3.05B |
High Estimate | 914.16M | -- | 3.45B | 3.72B |
Year Ago Sales | 9.33M | -- | 3B | 3.31B |
Sales Growth (year/est) | 9,032.90% | -- | 10.60% | 6.60% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | 0.64 | 0.69 | 0.84 | 0.84 |
EPS Actual | 0.7 | 1.01 | 1.07 | 0.99 |
Difference | 0.06 | 0.32 | 0.23 | 0.15 |
Surprise % | 9.40% | 46.40% | 27.40% | 17.90% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | 0.82 | 0.96 | 3.8 | 3.97 |
7 Days Ago | 0.82 | 0.96 | 3.77 | 3.94 |
30 Days Ago | 0.67 | 0.95 | 3.79 | 3.96 |
60 Days Ago | 0.68 | 0.96 | 3.81 | 3.98 |
90 Days Ago | 0.61 | 0.9 | 3.68 | 3.81 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | 1 | 1 |
Up Last 30 Days | -- | -- | 3 | 4 |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | RDY | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 17.10% | -- | -- | 1.50% |
Next Qtr. | -5.00% | -- | -- | 11.40% |
Current Year | 15.20% | -- | -- | 5.20% |
Next Year | 4.50% | -- | -- | 13.40% |
Next 5 Years (per annum) | 0.21% | -- | -- | 11.09% |
Past 5 Years (per annum) | 21.80% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Maintains | Barclays: Overweight to Overweight | 1/29/2024 |
Maintains | Barclays: Overweight to Overweight | 6/1/2023 |
Maintains | Barclays: Overweight | 10/31/2022 |
Maintains | Barclays: Overweight | 10/25/2022 |
Maintains | Barclays: Overweight | 9/12/2022 |
Maintains | Barclays: Overweight | 7/25/2022 |
Related Tickers
LFCR Lifecore Biomedical, Inc.
6.33
-1.86%
SUNPHARMA.NS Sun Pharmaceutical Industries Limited
1,485.75
+0.07%
PBH Prestige Consumer Healthcare Inc.
70.13
-1.53%
PCRX Pacira BioSciences, Inc.
25.90
-3.39%
CTLT Catalent, Inc.
55.95
-0.14%
TAK Takeda Pharmaceutical Company Limited
13.23
-1.12%
HLN Haleon plc
8.35
-0.71%
DIVISLAB.NS Divi's Laboratories Limited
3,813.80
+1.20%
INDV Indivior PLC
18.81
+0.97%
NBIX Neurocrine Biosciences, Inc.
138.97
-0.80%